RhumbLine Advisers’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

RhumbLine Advisers’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3	Closed	-$17	–	4378
2023 Q2	$17	Buy	+3	New	+$20	﹤0.01%	4382
2022 Q2	–	Sell	-2,616	Closed	-$73K	–	3286
2022 Q1	$73K	Sell	2,616 -134	-5%	-$4.88K	﹤0.01%	2942
2021 Q4	$125K	Sell	2,750 -14	-0.5%	-$942	﹤0.01%	2914
2021 Q3	$230K	Buy	2,764 +69	+3%	+$5.71K	﹤0.01%	2858
2021 Q2	$256K	Buy	+2,695	New	+$320K	﹤0.01%	2851
2014 Q2	–	Sell	-17	Closed	-$37K	–	3078
2014 Q1	$37K	Sell	17 -1	-6%	-$2.49K	﹤0.01%	2969
2013 Q4	$42K	Hold	18	–	–	﹤0.01%	3003
2013 Q3	$51K	Hold	18	–	–	﹤0.01%	2970
2013 Q2	$170K	Buy	+18	New	+$139K	﹤0.01%	3066

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PPW

Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

RhumbLine Advisers's ONCT Position: Q3 2023 in Review

RhumbLine Advisers sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2023, closing a stake of 3 shares — an estimated $17 sold.

RhumbLine Advisers first reported a position in ONCT in Q2 2013 and held it in 9 quarters. The position peaked at $256K in Q2 2021. 50 funds tracked by Wall St. Rank hold ONCT as of Q3 2023.

RhumbLine Advisers reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
RhumbLine Advisers sold 3 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $17.
RhumbLine Advisers first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
RhumbLine Advisers's Oncternal Therapeutics, Inc. Common Stock position peaked at $256K in Q2 2021.
50 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2023.

Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.